[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620240":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":58,"collaborators":25,"id":61,"slug":25,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":25,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":84,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Fayoum University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group L","ACTIVE_COMPARATOR","Active comparator group Group (L) recieves IV lidocaine 1.5mg\u002Fkg slowly before induction of anesthesia then lidocaine infusion starts at a rate of 2mg\u002Fkg\u002Fh",[13],"Drug: Lidocaine",{"label":15,"type":10,"description":16,"interventionNames":17},"Group D","Active comparator group (D) recieves IV dexmedetomidine bolus dose of 1mcg\u002Fkg over 10 minutes before induction of anesthesia followed by continous infusion at 0.4mcg\u002Fkg\u002Fh until the end of surgery",[18],"Drug: Dexmedetomidine",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dexmedetomidine","Group (D) recieves Dexmedetomidine bolus 1mcg\u002Fkg over 10 minutes before induction of anesthesia followed by continous infusion at 0.4 mcg\u002Fkg\u002Fh until the end of surgery",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Lidocaine","Group (L) recieves IV lidocaine 1.5 mg\u002Fkg slowly before induction of anesthesia then lidocaine infusion starts at a rate of 2mg\u002Fkg\u002Fh",[9],[31],{"name":32,"affiliation":25,"role":33},"Khaled E Tolba, MBBCH","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","01002568304","ket11@fayoum.edu.eg",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":25},"Mohamed A Hamed, MD","01010509736",[43],{"facility":44,"status":25,"city":45,"state":25,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"FayoumU","Al Fayyum","63511","Egypt",{"type":49,"coordinates":50},"Point",[51,52],30.8418,29.30995,{"lat":52,"lon":51},[55,56,57],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":40,"role":36,"phone":41,"phoneExt":25,"email":25},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Khaled Eid Tolba Abo Elwa","Doctor","100620240",false,"NCT07355049","The Effect of Dexmedetomidine Versus Lidocaine on Emergence Agitation.","The Effect of Intravenous Dexmedetomidine Versus Intravenous Lidocaine on the Emergence Agitation After Endoscopic Sinus Surgery. A Prospective, Randomized, Double-blind Controlled Trial.","Inclusion Criteria:\n\n* Age : 18-60\n* ASA Physical Status I or II\n* Elective endoscopic sinus surgery under general anesthesia .\n\nExclusion Criteria:\n\n* Refusal to participate\n* Mental retardation or inability to communicate\n* Allergy to anesthetics or study medications .\n* Chronic use of beta blockers .\n* significant hepatic, neurologic, cardiovascular or respiratory disease .\n* BMI\\>35 kg\u002Fm2","ALL","18 Years","60 Years",{"count":71,"type":72},80,"ESTIMATED","INTERVENTIONAL",[75],"NA","The effect of intravenous dexmedetomidine versus intravenous lidocaine on the emergence agitation after endoscopic sinus surgery.",[78],"Emergence Agitation",[80,81,82,83],"Emergence agitation","Intravenous dexmedetomidine","Endoscopic sinus surgery","Intravenous lidocaine","NOT_YET_RECRUITING","2026-01-20",{"date":87,"type":88},"2026-01-21","ACTUAL",{"date":90,"type":72},"2025-12-21",{"date":92,"type":72},"2026-02-01",{"name":5,"class":6},1]